Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus.
The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.
Current Team (8)Update
Funding Rounds (4) - $143.4MUpdate
Board Members and Advisors (10)Update
Osage University Partners is a venture capital fund investing in start-ups that commercialize...
Healthcare-focused Investment Group
Early-Stage Biotech Investment
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on...
Avalon Ventures is an early stage venture capital fund focused on information technology and life...
Novo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk...
OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under...
6275 Nancy Ridge Drive,
San Diego, CA 92121